Last reviewed · How we verify

California Allergy and Asthma Medical Group, Inc. — Portfolio Competitive Intelligence Brief

California Allergy and Asthma Medical Group, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mometasone furoate 220 Mometasone furoate 220 marketed
Mometasone furoate 440 Mometasone furoate 440 marketed Inhaled corticosteroid Glucocorticoid receptor Respiratory / Allergy / Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chiesi Farmaceutici S.p.A. · 1 shared drug class
  2. Dey · 1 shared drug class
  3. Fujian Medical University Union Hospital · 1 shared drug class
  4. GlaxoSmithKline · 1 shared drug class
  5. Imperial College London · 1 shared drug class
  6. Intech Biopharm Ltd. · 1 shared drug class
  7. Istituto per la Ricerca e l'Innovazione Biomedica · 1 shared drug class
  8. AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for California Allergy and Asthma Medical Group, Inc.:

Cite this brief

Drug Landscape (2026). California Allergy and Asthma Medical Group, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/california-allergy-and-asthma-medical-group-inc. Accessed 2026-05-17.

Related